Syndax PharmaceuticalsSNDX
About: Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Employees: 184
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
170% more call options, than puts
Call options by funds: $6.62M | Put options by funds: $2.46M
50% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 58
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
10% more funds holding in top 10
Funds holding in top 10: 10 [Q1] → 11 (+1) [Q2]
3% more funds holding
Funds holding: 188 [Q1] → 194 (+6) [Q2]
5.08% less ownership
Funds ownership: 108.32% [Q1] → 103.24% (-5.08%) [Q2]
18% less capital invested
Capital invested by funds: $2.19B [Q1] → $1.8B (-$389M) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Stifel Bradley Canino 42% 1-year accuracy 16 / 38 met price target | 108%upside $41 | Buy Maintained | 14 Oct 2024 |
Citigroup Yigal Nochomovitz 56% 1-year accuracy 24 / 43 met price target | 73%upside $34 | Buy Maintained | 16 Aug 2024 |
HC Wainwright & Co. Edward White 30% 1-year accuracy 37 / 125 met price target | 128%upside $45 | Buy Maintained | 15 Aug 2024 |
B of A Securities Jason Zemansky 78% 1-year accuracy 7 / 9 met price target | 57%upside $31 | Buy Maintained | 15 Aug 2024 |
Barclays Peter Lawson 46% 1-year accuracy 13 / 28 met price target | 67%upside $33 | Overweight Maintained | 15 Aug 2024 |
